Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.

Oncotarget - 20 Oct 2015

Martin-Castillo Begoña, Lopez-Bonet Eugeni, Cuyàs Elisabet, Viñas Gemma, Pernas Sonia, Dorca Joan, Menendez Javier A

Abstract excerpt

Clinically HER2+ (cHER2+) breast cancer (BC) can no longer be considered a single BC disease entity in terms of trastuzumab responsiveness. Here we propose a framework for predicting the response of cHER2+ to trastuzumab that integrates the molecular distinctions of intrinsic BC subtypes with recent knowledge on cancer stem cell (CSC) biology. First, we consider that two interchangeable populations of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aldehyde Dehydrogenase
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epigenesis, Genetic

Share to Epithelial-Mesenchymal Transition

Share to Hyaluronan Receptors

Share to Neoplastic Stem Cells

Share to Receptor, ErbB-2

Share to Trastuzumab

Source

Open in PubMed Open full text

Identifiers

PMID: 26474458
DOI: 10.18632/oncotarget.6094
PMCID: PMC4741696

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.PMID 26474458Read ↗

Basal/HER2 breast carcinomasSemantic proximity Read ↗

Cancer stem cells and HER2 positive breast cancer: The story so farSemantic proximity Read ↗

Therapeutic vulnerabilities in triple negative breast cancer: Stem-like traits explored within molecular classification.Semantic proximity Read ↗

Cancer stem cells are prevalent in the basal-like 2 and mesenchymal triple-negative breast cancer subtypes in vitroSemantic proximity Read ↗

Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer.Semantic proximity Read ↗

Understanding breast cancer stem cell heterogeneity: time to move on to a new research paradigmSemantic proximity Read ↗

Sequencing of breast cancer stem cell populations indicates a dynamic conversion between differentiation states in vivo.Semantic proximity Read ↗

Breast cancer stem cells mediated CD8 <sup>+</sup> T cell exhaustion among different molecular subtypes of breast cancer regulated via NOTCH1/RBPJ/PD-L1 axisSemantic proximity Read ↗

Breast-cancer stem cells-beyond semantics.Semantic proximity Read ↗

Implications of Different Cancer Stem Cell Phenotypes in Breast Cancer.Semantic proximity Read ↗

Immunotherapy Implication of Signature-Guided Biomarker Discovery for Trastuzumab-Resistant HER2-Positive Breast CancerSemantic proximity Read ↗

HER-2, Notch, and Breast Cancer Stem Cells: Targeting an Axis of EvilSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.